About This Event

Acrivon Therapeutics (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, visits the Nasdaq MarketSite in Times Square.

In honor of the occasion, Peter Blume-Jensen, M.D., Ph.D., Founder, President and Chief Executive Officer of Acrivon, rings the Closing Bell.